Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iloprost in the Management of Vaso-occlusive Crises in Sickle Cell Disease
NCT07498309Phase 3Not yet recruiting
- Sponsor
- Rouen University Hospital
- Start
- Sep 2026
- Primary completion
- Mar 2030
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in vaso-occlusive crisis (VOC) comparing Iloprost with Placebo (2 arms). Primary endpoint: Opioid consumption at 28 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
iloprost
03
Conditions
vaso-occlusive crisis (VOC)
Beyond the preview
Go deeper on NCT07498309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07498309.